Equate Lansoprazole Delayed Release

The dosage of Lansoprazole varies significantly based on the condition being treated. For the short-term treatment of active duodenal ulcers, the standard adult dose is 15 mg once daily for 4 weeks. If the goal is the treatment of an active benign gastric ulcer, the dose is typically increased to 30 mg once daily for up to 8 weeks.

For Gastroesophageal Reflux Disease (GERD) with no esophageal erosions, 15 mg once daily for up to 8 weeks is common. However, if Erosive Esophagitis is present, the dose is usually 30 mg once daily for 8 weeks, followed by a maintenance dose of 15 mg once daily to prevent relapse. In cases of NSAID-induced ulcers, 30 mg once daily is used for treatment, while 15 mg once daily is used for prevention in at-risk patients. For H. pylori eradication, Lansoprazole 30 mg is typically given twice daily (every 12 hours) in combination with antibiotics for 10 to 14 days. Hypersecretory conditions like Zollinger-Ellison Syndrome require much higher doses, often starting at 60 mg once daily and potentially increasing up to 180 mg per day in divided doses.

Lansoprazole is FDA-approved for use in pediatric patients for the short-term treatment of symptomatic GERD and erosive esophagitis.

• Children 1 to 11 years old: Dosing is weight-based. For those weighing ≤30 kg, the dose is 15 mg once daily. For those weighing >30 kg, the dose is 30 mg once daily. Treatment usually lasts up to 12 weeks.
• Adolescents 12 to 17 years old: The dosing is generally the same as adult dosing (15 mg for GERD, 30 mg for erosive esophagitis) for up to 8 weeks.
• Infants under 1 year: Lansoprazole has not been shown to be effective for GERD in infants under 1 year of age and is generally not recommended in this population.

Renal Impairment

No dosage adjustment is typically required for patients with renal impairment or those undergoing hemodialysis, as the drug is primarily metabolized by the liver.

Hepatic Impairment

In patients with mild to moderate hepatic impairment, adjustments are usually unnecessary. However, for those with severe hepatic impairment (Child-Pugh Class C), healthcare providers should consider a dose reduction, often limiting the daily dose to 15 mg, as the drug's half-life is significantly prolonged in these patients.

Elderly Patients

While the clearance of Lansoprazole may be slightly reduced in the elderly, dosage adjustments are not typically required unless there is concurrent severe liver disease. However, the 30 mg daily dose should generally not be exceeded in this population unless clinically necessary.

To ensure maximum efficacy, Lansoprazole should be taken at least 30 to 60 minutes before a meal, preferably breakfast. The capsules should be swallowed whole; they should not be crushed or chewed, as this destroys the enteric coating that protects the medication from stomach acid.

For patients who cannot swallow capsules, the delayed-release capsules can be opened and the intact granules sprinkled on one tablespoon of soft food (such as applesauce, yogurt, or cottage cheese) and swallowed immediately. Alternatively, the granules can be mixed with 60 mL of orange juice, apple juice, or tomato juice and swallowed. For the Orally Disintegrating Tablet (ODT), the tablet should be placed on the tongue and allowed to dissolve; it should not be chewed. It can be swallowed with or without water.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Consistency is key to maintaining acid suppression.

Lansoprazole has a high safety profile, and significant toxicity from an acute overdose is rare. Symptoms of a massive overdose might include nausea, vomiting, or diarrhea. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention. Because Lansoprazole is highly protein-bound, it is not significantly removed by hemodialysis.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this can lead to a return of symptoms or "rebound" acid hypersecretion.

Lansoprazole is generally well-tolerated by most patients. The most frequently reported side effects, occurring in roughly 1% to 10% of clinical trial participants, include:

• Diarrhea: This is the most common complaint. It is usually mild and self-limiting but can sometimes be persistent.
• Abdominal Pain: Some patients report cramping or general discomfort in the stomach area shortly after starting the medication.
• Nausea: A feeling of sickness in the stomach, which often resolves as the body adjusts to the drug.
• Constipation: While diarrhea is more common, some patients experience a slowing of bowel movements.
• Headache: This is a frequent side effect across the entire PPI class.

• Dizziness: Some patients may feel lightheaded or unsteady.
• Dry Mouth: A decrease in saliva production (xerostomia).
• Skin Rash or Itching: Mild allergic skin reactions can occur.
• Flatulence: Increased gas or bloating.
• Fatigue: A general sense of tiredness or lack of energy.

• Taste Perversion: A persistent metallic or bitter taste in the mouth.
• Leukopenia/Thrombocytopenia: A rare decrease in white blood cells or platelets, which requires monitoring by a healthcare provider.
• Hepatotoxicity: Rare elevations in liver enzymes or jaundice (yellowing of the skin/eyes).
• Gynaecomastia: Swelling of breast tissue in males.

While rare, certain side effects of Lansoprazole are serious and require urgent medical intervention.

> Warning: Stop taking Lansoprazole and call your doctor immediately if you experience any of the following:

1. 1Clostridioides difficile-Associated Diarrhea (CDAD): PPIs like Lansoprazole can change the bacterial balance in the gut. If you experience watery stools, persistent stomach pain, and fever that does not go away, it may indicate a serious bacterial infection.
2. 2Bone Fractures: Long-term use or high doses of PPIs have been linked to an increased risk of hip, wrist, or spine fractures, likely due to interference with calcium absorption.
3. 3Hypomagnesemia: Prolonged use (usually over a year) can lead to low magnesium levels. Symptoms include tremors, arrhythmias (irregular heartbeat), muscle spasms, or seizures.
4. 4Acute Interstitial Nephritis (AIN): This is a sudden inflammation of the kidneys that can occur at any time during treatment. Symptoms include decreased urination, blood in the urine, or swelling in the legs.
5. 5Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus (CLE): PPIs can trigger or worsen autoimmune conditions. Watch for joint pain or a skin rash on the cheeks or arms that worsens in sunlight.
6. 6

Patients who remain on Lansoprazole for several years may face specific risks. One common finding is Fundic Gland Polyps, which are small, benign growths in the upper part of the stomach. These are usually harmless but should be monitored during endoscopy. There is also emerging research regarding a potential link between long-term PPI use and Chronic Kidney Disease (CKD) and Dementia, although these associations are still being studied and are not yet definitively proven to be causative. Furthermore, reduced stomach acid can lead to a slight increase in the risk of community-acquired pneumonia, as the "acid barrier" that normally kills inhaled or ingested pathogens is weakened.

As of 2026, there are no FDA Black Box Warnings for Lansoprazole. However, the FDA has issued several safety communications regarding the risks of long-term use, particularly concerning bone fractures, magnesium depletion, and C. difficile infections.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Monitoring and periodic review of the need for continued therapy are essential for long-term safety.

Lansoprazole is a potent medication that requires careful clinical oversight. It is not intended for the immediate relief of occasional heartburn; it may take 1 to 4 days for the full acid-suppressing effect to be realized. Patients should be aware that symptomatic response to Lansoprazole does not preclude the presence of gastric malignancy. If symptoms persist despite treatment, further diagnostic testing, such as an endoscopy, may be necessary to rule out more serious conditions.

There are currently no FDA black box warnings for Lansoprazole. It is considered safe when used as directed for the appropriate duration. However, the absence of a black box warning does not mean the drug is without risk, especially when used chronically without medical supervision.

Allergic Reactions and Anaphylaxis

Serious hypersensitivity reactions, including anaphylaxis and angioedema (swelling of the face, lips, or throat), have been reported. If you have a known allergy to other PPIs like omeprazole, esomeprazole, or pantoprazole, you are at a high risk of cross-reactivity and should not take Lansoprazole.

Bone Fracture Risk

Multiple observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk is highest in patients receiving high doses (multiple daily doses) or long-term therapy (one year or longer). Patients should use the lowest dose and shortest duration of therapy appropriate to the condition being treated.

Severe Skin Reactions

Severe cutaneous adverse reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported with PPI use. Discontinue Lansoprazole at the first appearance of a skin rash or any other sign of hypersensitivity.

Hypomagnesemia

Hypomagnesemia (critically low magnesium) has been reported in patients treated with PPIs for at least three months, and in most cases, after a year of therapy. This can lead to serious adverse events including tetany, arrhythmias, and seizures. In many patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.

For patients on long-term Lansoprazole therapy, healthcare providers may recommend the following monitoring:

• Magnesium Levels: Baseline and periodic checks, especially for those also taking digoxin or diuretics.
• Vitamin B12 Levels: Periodic monitoring for patients on therapy for more than 3 years.
• Renal Function: Monitoring for signs of Acute Interstitial Nephritis or chronic kidney changes.
• Bone Density: For patients at high risk for osteoporosis, regular DEXA scans may be advised.

Lansoprazole generally does not interfere with the ability to drive or operate machinery. However, side effects like dizziness or visual disturbances occur in a small number of patients. If you experience these symptoms, avoid hazardous tasks until you know how the medication affects you.

There is no direct chemical interaction between alcohol and Lansoprazole. However, alcohol is a known gastric irritant that can increase stomach acid production and worsen the symptoms of GERD or ulcers. Consuming alcohol may counteract the beneficial effects of the medication.

Abruptly stopping Lansoprazole after long-term use can lead to Rebound Acid Hypersecretion. This occurs because the body tries to compensate for the suppressed acid by overproducing gastrin. When the drug is removed, acid levels can spike higher than they were before treatment, causing a temporary worsening of symptoms. Healthcare providers often recommend a gradual tapering of the dose or switching to H2 blockers temporarily when discontinuing the drug.

> Important: Discuss all your medical conditions, including any history of liver disease or osteoporosis, with your healthcare provider before starting Lansoprazole.

• Rilpivirine: This HIV medication requires an acidic environment in the stomach for proper absorption. Lansoprazole significantly reduces rilpivirine plasma concentrations, which can lead to loss of virologic response and drug resistance. This combination is strictly contraindicated.
• Nelfinavir: Similar to rilpivirine, nelfinavir absorption is severely impaired by PPIs, reducing its effectiveness against HIV.

• Methotrexate: Case reports and pharmacokinetic studies suggest that concomitant use of PPIs with methotrexate (primarily at high doses) may elevate and prolong serum levels of methotrexate and its metabolite, potentially leading to methotrexate toxicities (such as kidney damage or bone marrow suppression).
• Warfarin: Lansoprazole may increase the blood-thinning effects of warfarin. Patients taking both should have their International Normalized Ratio (INR) and prothrombin time monitored closely to prevent bleeding complications.
• Digoxin: By increasing gastric pH, Lansoprazole can increase the absorption of digoxin. This may lead to digoxin toxicity, characterized by nausea, vomiting, and heart rhythm disturbances. Magnesium levels must also be monitored, as low magnesium increases digoxin's cardiotoxicity.

• pH-Dependent Drugs: Many medications require stomach acid to dissolve and be absorbed. Lansoprazole can significantly reduce the absorption of:
• Antifungals: Ketoconazole, Itraconazole.
• Iron Salts: Ferrous sulfate.
• Mycophenolate Mofetil (MMF): Used in organ transplants; reduced acid can lower MMF exposure.
• Erlotinib/Dasatinib: Certain cancer medications.
• Sucralfate: This medication can delay the absorption of Lansoprazole. Lansoprazole should be taken at least 30 minutes before sucralfate.
• Theophylline: Lansoprazole may cause a minor (approx. 10%) increase in the clearance of theophylline. While usually not clinically significant, some patients may require dose adjustments of theophylline.

Food is the most significant "interaction" for Lansoprazole. Ingesting the drug with or immediately after a meal reduces its bioavailability by up to 70%. For the drug to work effectively, it must be absorbed and reach the parietal cells before they are stimulated by a meal. Therefore, it should always be taken on an empty stomach, 30 to 60 minutes before eating.

• St. John's Wort: This herbal supplement is a potent inducer of the CYP2C19 and CYP3A4 enzymes. Taking it with Lansoprazole can significantly decrease the concentration of the drug in the blood, rendering it less effective.
• Ginkgo Biloba: May also induce the metabolism of Lansoprazole, though the effect is typically less pronounced than with St. John's Wort.

• Chromogranin A (CgA): Increased gastric pH leads to an increase in serum CgA levels, which is a marker used to detect neuroendocrine tumors. This can cause false-positive results. Lansoprazole should be stopped at least 14 days before a CgA test.
• Urine Screening for THC: Some PPIs have been reported to cause false-positive urine screening tests for tetrahydrocannabinol (THC/marijuana). A confirmatory test (like GC/MS) should be used.
• Secretin Stimulation Test: PPIs can cause a hyper-response to secretin, mimicking the results seen in gastrinoma. Treatment should be paused prior to testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as many interactions require dose timing adjustments or specialized monitoring.

Lansoprazole must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: Patients with a documented allergy to Lansoprazole or any component of its formulation (e.g., the granules, the capsule shell) must not take the drug. Symptoms of hypersensitivity include rash, urticaria (hives), angioedema, and anaphylaxis.
2. 2Cross-Sensitivity with other PPIs: There is a high degree of cross-reactivity among the proton pump inhibitor class. If a patient has had a severe allergic reaction to omeprazole, esomeprazole, pantoprazole, or rabeprazole, Lansoprazole is absolutely contraindicated.
3. 3Concomitant Rilpivirine Use: As noted in the interactions section, the use of rilpivirine-containing products with any PPI is contraindicated due to the risk of HIV treatment failure.

In these situations, the healthcare provider will perform a careful risk-benefit analysis:

• Severe Hepatic Impairment: While not an absolute contraindication, the significantly prolonged half-life in Child-Pugh Class C patients requires extreme caution and dose reduction. The risk of drug accumulation is high.
• Osteoporosis or High Fracture Risk: Patients with existing low bone mineral density or those at high risk for fractures (e.g., postmenopausal women not on estrogen) should only use Lansoprazole if the benefits clearly outweigh the risks, and they should be on adequate calcium and vitamin D supplementation.
• Hypomagnesemia: Patients who already have low magnesium levels should have this corrected before starting long-term PPI therapy, as the drug will likely exacerbate the condition.
• Gastric Malignancy: If a patient has symptoms of a stomach tumor (weight loss, persistent vomiting, difficulty swallowing), Lansoprazole should not be started until malignancy is ruled out, as the drug can mask the symptoms of stomach cancer and delay diagnosis.

Lansoprazole belongs to the benzimidazole class of compounds. Beyond other PPIs, patients should be cautious if they have had reactions to other benzimidazoles (such as certain anthelmintic drugs like albendazole), although cross-reactivity with non-PPI benzimidazoles is clinically rare.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies and your current liver function, before prescribing Lansoprazole to ensure it is safe for you.

Lansoprazole was historically classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Available data from observational studies over several decades have not shown an increased risk of major birth defects or adverse pregnancy outcomes associated with PPI use during the first trimester. However, Lansoprazole should only be used during pregnancy if clearly needed and under the direct supervision of a healthcare provider. It is generally reserved for cases where H2 blockers (like famotidine) have failed to provide relief.

It is not known whether Lansoprazole is excreted in human milk. However, in animal studies, Lansoprazole was shown to be present in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (such as interference with the infant's own stomach acid production), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Lansoprazole is approved for use in children aged 1 to 17 years for the treatment of GERD and erosive esophagitis. It has been shown to be safe and effective in these age groups when dosed appropriately by weight. However, it is NOT approved for use in infants under the age of 1. Clinical trials in infants failed to show that Lansoprazole was more effective than a placebo for symptoms of reflux, and there are concerns about potential side effects in very young children, such as an increased risk of respiratory and gastrointestinal infections.

In clinical trials, no overall differences in safety or effectiveness were observed between elderly subjects (65 years and older) and younger subjects. However, the elderly are more likely to have decreased hepatic function and may be taking multiple other medications (polypharmacy), increasing the risk of drug interactions. Furthermore, the elderly are at a higher baseline risk for bone fractures and C. difficile infections, making the complications of PPI therapy more dangerous in this population. Healthcare providers often recommend using the lowest effective dose for the shortest possible time in older adults.

Pharmacokinetic studies in patients with varying degrees of renal impairment (including those on dialysis) show that no dosage adjustment is necessary. The drug is primarily cleared by the liver. However, patients with renal disease should still be monitored for the rare occurrence of Acute Interstitial Nephritis, which can worsen existing kidney problems.

For patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, no initial dose adjustment is typically required. For patients with severe hepatic impairment (Child-Pugh C), the exposure to the drug (AUC) can increase by up to 500%. In these cases, a dose reduction is mandatory, typically to 15 mg once daily, to prevent toxicity.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any history of liver or kidney disease.

Lansoprazole is a specific inhibitor of the gastric H+/K+ ATPase enzyme system, also known as the "proton pump." At the molecular level, Lansoprazole is a weak base that accumulates in the acidic environment of the parietal cell's secretory canaliculi. Here, it is protonated and converted into its active form, a thiophilic sulfenamide. This active metabolite forms a covalent disulfide bond with the cysteine residues of the alpha-subunit of the proton pump. This binding is irreversible, effectively poisoning the pump and preventing the secretion of hydrogen ions into the gastric lumen. Because this is the final step in acid production, Lansoprazole inhibits both basal (resting) and stimulated (post-meal) acid secretion, regardless of the stimulus (gastrin, acetylcholine, or histamine).

Lansoprazole produces a dose-dependent inhibition of gastric acid secretion. A single 30 mg oral dose can inhibit stimulated acid secretion by approximately 80% to 97%. The onset of action is rapid, with a significant increase in gastric pH occurring within 1 to 3 hours. However, because not all proton pumps are active or inhibited with the first dose, it takes about 3 to 5 days of daily dosing to reach a "steady state" of maximal acid suppression. After the drug is discontinued, acid secretory activity gradually returns to baseline over 2 to 4 days as new proton pumps are synthesized by the parietal cells.

| Parameter | Value |

|---|---|

| Bioavailability | 80% - 85% (decreases with food) |

| Protein Binding | 97% (primarily to albumin) |

| Half-life | 1.5 - 2.0 hours (prolonged in liver disease) |

| Tmax | 1.7 hours (on an empty stomach) |

| Metabolism | Hepatic (CYP2C19 and CYP3A4) |

| Excretion | Renal 14-23%, Fecal/Biliary 66-76% |

Lansoprazole is chemically described as 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole. Its molecular formula is C16H14F3N3O2S, and it has a molecular weight of 369.36 g/mol. It is a white to brownish-white crystalline powder which is odorless. It is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; and practically insoluble in water. The presence of the trifluoroethoxy group distinguishes it from other PPIs and contributes to its specific metabolic profile.

Lansoprazole is classified as a Proton Pump Inhibitor (PPI). It belongs to the larger family of substituted benzimidazoles. Related medications in this class include omeprazole (Prilosec), esomeprazole (Nexium), pantoprazole (Protonix), and rabeprazole (Aciphex). While all PPIs share the same core mechanism of action, they differ in their metabolic pathways, potency, and FDA-approved indications.